Paeoniflorin-Isoliquiritigenin Composition Treats Pulmonary Fibrosis
Summary
The USPTO has published patent application US20260108548A1, assigned to Henan University of Chinese Medicine, covering a therapeutic composition of paeoniflorin and isoliquiritigenin for treating diffuse interstitial pulmonary fibrosis. The application was filed on October 8, 2023 (Application No. 19129203) and names nine inventors including Jiansheng Li and Peng Zhao. The composition is claimed to provide anti-inflammatory, antioxidant, and collagen deposition inhibition effects. Patent applications are informational publications — no examination or grant decision has been made.
“The composition according to the present invention is rich in raw materials, and has the effects of anti-inflammation, antioxidant, inhibiting collagen deposition, etc., and can be effectively used to treat diffuse interstitial pulmonary fibrosis with high economic and social benefits.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
The USPTO published patent application US20260108548A1 for a composition of paeoniflorin and isoliquiritigenin filed by Henan University of Chinese Medicine. The application claims the composition is useful for treating diffuse interstitial pulmonary fibrosis, with effects including anti-inflammation, antioxidant activity, and inhibition of collagen deposition.
Affected parties — pharmaceutical researchers, drug developers, and manufacturers working in pulmonary fibrosis therapeutics — should monitor this application as it proceeds through examination. The publication of a patent application does not constitute a grant of rights; competitors should assess whether their own R&D programs could overlap with the claimed composition and consider freedom-to-operate analysis.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITION OF PAEONIFLORIN AND ISOLIQUIRITIGENIN AND USE THEREOF
Application US20260108548A1 Kind: A1 Apr 23, 2026
Assignee
HENAN UNIVERSITY OF CHINESE MEDICINE
Inventors
Jiansheng LI, Yange TIAN, Suxiang FENG, Peng ZHAO, Zhouxin REN, Xueqing YU, Xuefang LIU, Haoran DONG, Shuguang YANG
Abstract
The present invention relates to a composition of paeoniflorin and isoliquiritigenin and application thereof. The composition according to the present invention is rich in raw materials, and has the effects of anti-inflammation, antioxidant, inhibiting collagen deposition, etc., and can be effectively used to treat diffuse interstitial pulmonary fibrosis with high economic and social benefits.
CPC Classifications
A61K 31/7048 A61K 31/12 A61P 11/00
Filing Date
2023-10-08
Application No.
19129203
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.